GLP-1 vs. Traditional Diabetes Medicines: Which is Best for Weight Loss?

For many years, the treatment for type 2 diabetes has involved selecting from a few medications mostly focused on controlling blood sugar levels, but offering weight impact varying from no effect to negative. The introduction of a new generation of injectable medicines made a difference never experienced before in the industry.

Nowadays, patients and physicians face a different question: they should not only determine which medication does the best job of controlling blood sugar levels, but also which medication would help limit the excessive weight gain that commonly contributes to the development of the disease. Understanding the difference between the old and new methods is important.

Key Takeaways

Traditional diabetes medicines vary significantly in their effect on body weight, with some causing weight gain, some being weight-neutral, and a few producing modest weight loss. GLP-1 receptor agonists produce clinically significant weight loss through hormonal appetite suppression, a mechanism no older medicine class replicates. The right choice between older and newer agents depends on individual clinical profile, treatment goals, tolerability, and cost. For patients where weight management is as important a goal as blood sugar control, the evidence strongly favours newer hormonal agents over traditional options.

Why Diabetes Medicines and Weight Are So Closely Connected

The linkage between diabetes medication and weight loss should not be considered a minor detail. It is at the heart of managing type 2 diabetes effectively for the long term. Extra body weight, especially visceral fat, worsens insulin resistance, making blood sugar control more difficult.

This means that the more medicines are required to control blood sugar, the more weight gain takes place.

What Traditional Diabetes Medicines Do to Weight

Older diabetes medications work to lower blood glucose without relying on hormonal systems that influence appetite or fat metabolism.

Metformin is the most extensively used first-line oral medication for diabetes worldwide. It lowers glucose production in the liver and improves insulin sensitivity without affecting insulin production.

It does not lead to significant weight loss but could help patients lose a small amount of weight, which is why it is the most suitable option among traditional diabetes medications. However, the amount of weight loss it causes is usually small, averaging about 2-3 kg.

Sulfonylureas instead reduce blood glucose by increasing insulin secretion regardless of blood glucose level, leading to gradual weight gain, typically 2-4 kg, as tissues get used to high levels of insulin and the body starts to store fat. Using insulin also produces similar results, with those who use insulin treatment usually gaining 5 kg and more over time.

What GLP-1 Medicines Are and Why They Work Differently

These medications imitate glucagon-like peptide-1, a hormone produced naturally by the intestines after food intake. Activation of GLP-1 receptors in the food centres of the brain, endocrine pancreas, stomach and liver decreases hunger.

The GLP-1 Agonist Class and What It Covers

There is now a variety of GLP-1 Agonists available that differ in dosing intervals and target receptors. Some medications, such as liraglutide, require daily injections of the medicine, while others, such as semaglutide, require only a single injection a week.

There is also an oral formulation of semaglutide. This class of medicines is unique from older antidiabetic medicines due to its capacity to lower blood sugar levels and produce significant weight loss.

Comparing Weight Loss Outcomes Across Medicine Classes

The difference in Weight Loss outcomes between conventional medicine and GLP-1-based treatment is considerable. Metformin results in moderate weight loss of two to three percent. SGLT2 inhibitors are a more recent oral class of medication that lowers blood sugar levels by promoting glucose excretion through the urine, resulting in weight loss of three to four per cent. 

In comparison with these medications, GLP-1 receptor agonists have been shown to achieve average weight losses of ten to fifteen percent within their subjects.

Semaglutide and Its Clinical Evidence

Semaglutide has the largest amount of clinical data available among all GLP-1 agents currently available. Within the SUSTAIN and STEP programs conducted with the medicine for type 2 diabetes and weight loss, respectively, it consistently reduced HbA1c levels by more than 2% and allowed for weight loss of 12 to 15% over 68 weeks. 

Ozempic was developed as an injectable once-a-week medication based on the semaglutide compound for the treatment of type 2 diabetes. Its use has brought new opportunities to consider GLP-1 therapy in clinical practice and make it a priority instead of a last resort for patients focused on weight reduction.

The Dual Receptor Option

Mounjaro enables weight loss by activating GLP-1 and GIP receptors at the same time. GIP stimulates fat tissue metabolism in addition to GLP-1-induced hunger suppression.

SURMOUNT's clinical trials showed an average weight loss ranging from 15% to 22%, depending on the dose, which is higher than the results demonstrated by any kind of GLP-1 agent and resembles results relating to surgical weight loss procedures historically.

Managing Side Effects During Treatment

The main side effects of GLP-1-based therapy are gastrointestinal in nature. Nausea, diarrhoea, and decreased appetite are the most prevalent side effects at the start of treatment and after every dose modification. 

Traditional medicines have a different side effect profile. Metformin is known to cause gastrointestinal problems at the start of treatment, sulfonylureas often lead to hypoglycemia, and insulin requires monitoring of blood levels.

Who Benefits Most From GLP-1 Therapy

Individuals who can gain maximum advantage from GLP-1 therapy compared with older alternatives are those whose treatment requires effective control over both their weight and blood sugar level.

Those who already suffer from cardiovascular abnormalities that some GLP-1medicines are known to provide assistance with, and those who could not receive satisfactory treatment with metformin or other oral medication without gaining extra weight.

Importance of Follow-Up Care

Both traditional and newer diabetes medications require regular monitoring. Blood glucose, HbA1c, kidney function, and weight are tracked across all classes. When GLP-1 therapy is added to existing treatment, other medications, particularly insulin and sulfonylureas, may need dose reduction to avoid hypoglycaemia as blood sugar improves. Regular clinical review ensures the treatment plan stays matched to the patient's evolving metabolic profile.

What Is Worth Remembering

The comparison between GLP-1 medicines and traditional diabetes medications is not simply about which lowers blood sugar more effectively. It is about which approach best addresses the complete metabolic picture of a patient managing both type 2 diabetes and excess weight.

For patients where weight management matters as much as glycaemic control, the clinical evidence now points clearly toward GLP-1-based therapy as the more effective choice. For others where weight is not a concern, traditional medications continue to offer safe, effective, and significantly more affordable blood sugar management.

Disclaimer: This article is for general informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or modifying any diabetes medication or treatment plan.